Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the -common receptor.
Introduction
Sepsis is a complex clinical entity caused by an individual's systemic response to an infection with a wide range of clinical symptoms often leading to multiple organ dysfunction syndrome (MODS) and ultimately multiple organ failure (MOF). Despite a substantially improved knowledge of the pathophysiology of sepsis, the treatment of this condition is still a clinical challenge. To date, therapies have been mostly supportive and all specific therapeutic approaches, except early administration of antibiotics and "early goal directed therapy" 1, 2 , have failed to be translated successfully into the clinical setting. Hence, new pharmacological strategies are urgently needed to improve this condition. In sepsis some organs can escape relatively unscathed, whereas others become affected both early and severely 3 . The kidney is one such organ that can be affected early with the development of acute kidney injury (AKI).
This dysfunction is one of the most frequent and serious complications of sepsis and septic fold from baseline), or a reduction in urine output (≤ 0.5 ml/kg per h for more than 6 h) 5 . It is interesting to note that this definition does not take into consideration histological evidence of tissue injury and is solely based on rise in creatinine or fall in urinary output -even though the word injury may imply the existence of morphological evidence of injury 6 . Interestingly, the incidence of AKI increases with the severity of sepsis, occurring in 19 % of patients with sepsis, 23 % patients with severe sepsis and 51 % patients with septic shock 7 .
Sepsis occurs more frequently and severely in older patients 8 and there is some evidence that the elderly septic patient is more susceptible for the development of AKI 9 . Similarly, in animal models of experimental sepsis systemic inflammation and the release of proinflammatory cytokines are greater in older animals [10] [11] [12] and the severity of septic AKI was recently reported to be age-dependent in female mice 13 . It has been proposed that the increase in the severity of sepsis in aging animals is secondary to changes in gut flora (Hyde et al., 1990 ).
Emerging evidence suggests that the pathogenesis of septic renal dysfunction involves distinct mechanisms when compared to a non-septic etiology 14 . There is evidence in man, that the AKI caused by sepsis is not associated (or at least solely explained) by significant morphological changes such as extensive tubular necrosis 6, 15 . The proposed pathophysiological mechanisms of sepsis-associated AKI include systemic vasodilatation, intra-renal vasoconstriction, inflammation and bioenergetics failure 14, 16 6, 7, 17 .
The pleiotropic hormone erythropoietin (EPO) is known to possess organ protective properties, which are independent from its well-established hematopoietic effects 18 .
Endogenous EPO is primarily produced by renal cortical fibroblasts, and the fact, that erythropoietin receptors (EPO-R) are expressed in glomerular, endothelial and tubular epithelial cells 19, 20 , suggests endogenous EPO may function in a paracrine manner to limit the extent of injury after a noxious stimulus 19 . Furthermore, studies have proposed that the tissue protective effects of EPO are mediated through a 'tissue-protective' receptor, which is pharmacologically distinct from the classical hematopoietic EPO-R
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. This tissue protective receptor is a heterocomplex composed of EPO-R and the β-common receptor (βcR), which exhibits a lower affinity for EPO 22 . Over the years, EPO has been shown to be protective in various animal models of injury including cerebral ischemia 23, 24 , myocardial ischemia [25] [26] [27] , and renal injury [28] [29] [30] . Indeed, in a model of bilateral renal artery occlusion in the rat, EPO inhibits apoptotic cell death, promotes renal functional recovery, and enhances tubular epithelial regeneration 19 .
It should be noted that the effects of EPO in sepsis-induced AKI are controversial [31] [32] [33] [34] [35] [36] . Some studies report no beneficial effect of EPO in models of endotoxemia in the rat or pig 
Results

Effect of EPO on renal dysfunction in endotoxemic WT and βcR KO mice
When compared to sham mice treated with saline, WT mice subjected to 18 h of endotoxemia demonstrated a significant increase in both serum urea (7.3 ±. 0.27 vs. 33.1 ±.1.75 mmol/l, P<0.05, Figure 1A ) and serum creatinine (25.9 ± 0.92 vs. 57.1 ± 4.72 μmol/l, P<0.05, Figure   1C ), indicating the development of AKI. Administration of EPO significantly attenuated the rise in serum urea (33.1 ± 1.75 vs. 25.9 ± 3.2 mmol/l, P<0.05, Figure 1A ) and creatinine (57. Figure 1B ) and creatinine (27.8 ± 0.81 vs. 59.4 ± 5.06 μmol/l, P<0.05; Figure   1D ). Most notably, the renal dysfunction caused by endotoxemia in βcR KO mice was not attenuated by EPO (urea 33.0 ± 1.94 vs. 34 ± 1.27 mmol/l, P>0.05, Figure 1B ; creatinine 59.4 ± 5.06 vs. 54.9 ± 3.06 μmol/l, P>0.05, Figure 1D ). To gain a better understanding of the mechanisms underlying the observed renal dysfunction in endotoxemia, we carried out an extensive histological analysis in all experimental groups.
Effects
Evaluation by light microscopy (HE-staining) revealed that there was no overt morphological evidence of proximal tubular epithelial cell injury, interstitial edema, interstitial inflammation, vasculopathy or glomerular abnormality in any of the study groups (Figure 2A ). Therefore the results of the HE pathology evaluation produced no significant treatment-related changes.
To further investigate the potential role of apoptosis in the observed renal dysfunction, we analyzed all sections for the active fragment of caspase-3 (CCR3), which plays a key role in apoptosis. Immunohistochemical analysis for CCR3 revealed that When compared to kidneys from sham mice treated with saline, the kidneys of endotoxemic WT and βcR KO mice exhibited significant increases in the nuclear translocation of the p65 NF-ĸB subunit ( Figure 3D ), indicating the activation of NF-ĸB. Treatment of endotoxemic WT mice with EPO resulted in a significant reduction in nuclear translocation of p65 and, hence, inhibition of activation of NF-ĸB in the kidney ( Figure 3D ). In contrast, administration of EPO to endotoxemic βcR KO mice did not attenuate the nuclear translocation of p65 caused by LPS ( Figure 3D ).
The development of renal dysfunction in aging mice following cecal ligation and puncture (CLP).
The development of renal dysfunction in our short and severe model of polymicrobial sepsis Figure 4 ). To gain a better insight into where the βcR was expressed in the mouse kidneys, we attempted to detect the CSf2rb gene (which encodes the βcR, which was modified in the βcR knockout mice used in this study). We, therefore, isolated mRNA from medulla and cortex of the kidneys of WT sham mice and subjected the cDNA obtained after reverse transcription of mRNA to a PCR protocol with appropriate primers (see Tab. S1 online supplementary). We could clearly detect presence of βcR mRNA in both cortex and medulla ( Figure 6 ).
Effect of EPO on renal dysfunction in WT and
Discussion
Here we demonstrate that the administration of a large dose (1000 IU/kg s.c.) of EPO 1 h after LPS administration or CLP attenuates AKI. Most notably, we describe for the first time that the observed beneficial effects of EPO in WT mice subjected to either endotoxemia or sepsis were not observed in mice, which lacked the βcR. In 2004, Brines and colleagues proposed that the tissue protective effects of EPO and its derivatives might be mediated (at least in part), by the βcR 22 . The βcR is a signal transduction subunit, which is shared by the α-chain subunits of the IL-5, IL-3 and GM-CSF receptors 37 . The α-chains are able to bind their ligand with low affinity (1-100nM), but the hetero-receptors are not able to signal in the absence of the βcR.
On the other hand, the βcR does not measurably bind a ligand by itself, but it amplifies a signal once a ligand has bound (in the picomolar range) 38, 39 . The βcR is not required for erythropoiesis, as βcR KO mice have normal erythrocyte maturation 22 . The EPOR functionally associates with the βcR 40, 41 to generate an EPOR-βcR complex, the latter of which has been proposed to mediate the tissue-protective effects of EPO. In mice, the βcR was expressed (mRNA) in both cortex and medulla of the kidney. Our finding that the renoprotective effects of EPO in endotoxemia/sepsis are lost in βcR KO mice supports our hypothesis that the βcR is essential for the 'tissue-protective' effects of EPO in sepsis.
There is now increasing evidence that the renal dysfunction (AKI) associated with sepsis in patients is secondary to functional rather than structural changes. Although some morphological abnormalities have been reported in kidneys from patients, which died from sepsis, these changes were relatively small and are unlikely to account for the profound renal dysfunction observed in these patients. For instance, despite the high prevalence of clinical renal dysfunction (65%) in 20 patients, which died from sepsis and multiple organ dysfunction, only one septic patient had evidence of kidney necrosis. No renal tubular or glomerular cell apoptosis was seen in any of these septic patients. Hence, in patients without preexisting renal disease, renal histology did not reflect the severity of renal injury indicated by the decrease in kidney function (Hotchkiss CCM, 1999) . We show here that mice subjected to endotoxemia for 18 h have a profound renal dysfunction in the absence of overt morphological alterations or even increases in biomarkers of apoptosis (cleaved caspase-3) or proximal tubular injury (or KIM-1) in the kidney. As EPO did not affect any of the above (minimal) signs of injury, it is unlikely that the reduction in renal dysfunction afforded by EPO in sepsis is secondary to prevention of renal injury.
What, then, are the signaling events that are activated by EPO via the βcR? There is evidence that the beneficial effects of EPO are secondary to the activation of the survival kinase Akt [42] [43] [44] [45] . Akt is a member of the phosphoinositide 3-kinase signal transduction enzyme family, which regulates cellular activation, inflammatory responses, chemotaxis, and apoptosis 46 . When phosphorylated by its upstream regulator, phosphoinositide-dependent kinase, Akt modulates cell survival and growth 46 . We document here that EPO causes the activation of Akt in WT mice subjected to endotoxemia, while the activation of this pathway by EPO was lost in βcR KO mice. The above findings support the view that both, the βcR and the activation of Akt, are essential for the reported beneficial effects of EPO.
What, then, are the downstream targets of Akt? There is good evidence that activation of Akt results in Ser 9 phosphorylation of GSK-3β [47] [48] [49] . GSK-3β is a serine-threonine kinase that was originally recognized as a kinase that phosphorylates glycogen synthase. In contrast to most other kinases, GSK-3β is active in a resting cell state and is regulated by multiple signaling pathways including the Akt pathway, which inhibits this kinase by causing Ser 9 phosphorylation 47, 48 . Specific inhibitors of the activation GSK-3β attenuate the AKI caused by co-administration of LPS and peptidoglycan 50 and improve survival in endotoxemia 51 . Agents that activate the PI3K/Akt pathway 47 also inhibit GSK-3β. We have previously reported that insulin activates Akt, inhibits GSK-3β and reduces AKI caused by LPS and peptidoglycan 52 .
We report here that EPO enhances the phosphorylation of the Ser 9 residue of GSK-3β resulting in the inhibition of this kinase, which attenuates the renal dysfunction caused by LPS and peptidoglycan [53] [54] [55] . This effect of EPO was lost in βcR KO mice.
Downstream of GSK-3β, several studies have now reported an association between GSK-3β
and NF-κB activity in vitro 56, 57 and in vivo 50, 52 . Treatment of TNF-α stimulated hepatocytes with a specific GSK-3β inhibitor resulted in a decrease of the NF-κB-dependent gene transcription 58 . NF-κB is a transcriptional factor that plays an important role in regulating the transcription of a number of genes (e.g. iNOS, cyclooxygenase-2, IL-1, TNF, IL-6), especially those involved in producing mediators involved in local and systemic inflammation, such as cytokines, chemokines, cell adhesion molecules, apoptotic factors, and other mediators 59 .
The protective effects of inhibitors of GSK-3β in endotoxemia/sepsis have been attributed to inhibition of NF-ĸB secondary to either phosphorylation of Ser 536 on the p65 subunit of NF-ĸB 50 or prevention of the association of cAMP response element-binding (CREB) with p65 51 . In addition, GSK-3β may also inhibit the activation of NF-κB by phosphorylating and degrading IκBα, which is required to prevent NF-κB translocation 57 . All of these effects may contribute to the reported beneficial effects of inhibitors of GSK-3β in sepsis. We report here that EPO prevents the nuclear translocation of p65 and, hence, the activation of NF-ĸB. This effect of In conditions associated with sepsis, activation of eNOS is beneficial as the enhanced formation of NO causes local vasodilation, inhibits adhesion of platelets and neutrophils, and regulates angiogenesis 62, 63 . Agents that release NO or enhance the formation of endogenous NO may attenuate excessive intrarenal vasoconstriction and reduce renal dysfunction 64, 65 .
Thus, activation of eNOS (possibly secondary to activation of Akt) may contribute to the beneficial effects of EPO reported here.
All of the above findings support the view that the βcR is essential for the following effects of EPO in mice with endotoxemia: 1) reduction of AKI; 2) activation of Akt; 3) activation of eNOS; 4) inhibition of GSK-3β; and 5) inhibition of the activation of NF-ĸB.
In order to investigate whether the βcR is also essential for the effects of EPO in polymicrobial sepsis, we developed a model of CLP induced AKI. We found that the degree of renal dysfunction increased with the age of the animals. We were unable to document a significant degree of AKI at 24 h after CLP in young (two and five months old) mice, while eight months old mice exhibited a very large increase in creatinine within 24 h after CLP. Most notably, administration of EPO (at 1 h after CLP) attenuated the AKI caused by polymicrobial sepsis in aging mice. In order to investigate the role of the βcR in this effect of EPO, we bred agedmatched βcR KO mice. Using these animals, we demonstrate that the beneficial effects of EPO were lost in eight months old βcR KO mice.
In conclusion, our findings show convincingly for the first time that the βcR is essential in the reduction of the acute renal dysfunction caused by EPO in sepsis as well as all of the signaling events traditionally associated with the well-documented beneficial effects of EPO.
Methods Animals
The animal protocols followed in this study were approved by the local Animal Use and Care 
Endotoxemia
In the model of endotoxemia-induced AKI, mice received either LPS (9 mg/kg in 5 ml/kg 0.9 % saline i.p.) or vehicle (5 ml/kg 0.9 % saline i.p.). One hour after induction of endotoxemia, mice were treated either with EPO (1000 IU recombinant human EPO in 10 ml/kg 0.9 % saline) or vehicle (10 ml/kg 0.9 % saline s.c.). Sham mice were not subjected to LPS-injection, but were otherwise treated in the same way. At 18 h the experiment was terminated and organ and blood samples were collected for quantification of organ injury. WT mice and βcR KO mice 
Polymicrobial sepsis
In this study we developed a 24 h model of septic AKI induced by CLP in aged mice. We followed the original CLP protocol introduced by Wichterman and co-workers 66 with slight modifications, such as the antibiotic therapy (Imipenem/Cilastin; 20 mg/kg) and analgesia (buprenorphine; 0.05 mg/kg), which were administered 6 h after surgery and every 12 h after that. The detailed surgical procedure is described in the online supplementary file. To evaluate the time course of the development of renal dysfunction in mice of different ages, serum creatinine was measured in two, five and eight months old WT mice 24 h after CLP surgery. 
Quantification of organ injury
All mice were anesthetized with 1.5 ml/kg i.p. of a ketamine (100 mg/ml)/xylazine (20 mg/ml) solution in a 2:1 ratio before being sacrificed. Approximately 1 ml of blood was collected by cardiac puncture into non-heparinized syringes and immediately decanted into serum gel S/1.3 tube (Sarstedt, Germany), after which the heart was removed to terminate the experiment. The samples were centrifuged at 9900 g for 5 min to separate serum, which was sent to an independent laboratory (IDEXX Laboratories, Buckinghamshire, UK) for analyses of serum creatinine and urea as markers of renal dysfunction as described in detail in the online supplement file. Additionally, kidney samples were taken, snap frozen and stored at - 
Western Blot Analysis
Quantitative Western blot analysis was carried out as described previously 67 .
We Briefly, the medulla and the cortex were carefully dissected from the kidney and snap frozen.
Samples were homogenized and RNA was extracted using RNeasy Mini Kit (Quiagen, 
Materials
Unless otherwise stated, all compounds in this study were purchased from Sigma-Aldrich
Company Ltd (Poole, Dorset, UK). Antibodies for western blot analysis were purchased from Santa Cruz Biotechnologies (Middlesex, UK). All solutions were prepared using non-pyrogenic saline (0.9 % [w/v] NaCl; Baxter Healthcare Ltd., Thetford, Norfolk, UK). Recombinant human EPO (epoetin beta) was manufactured by Roche Diagnostics (Sussex, UK).
Statistical Analyses
All values described in the text and figures are presented as mean ± standard error of the mean (SEM) of n observations, where n represents the number of animals studied. Statistical analysis was performed using GraphPad Prism 5.0d (GraphPad Software, San Diego, California, USA). Data without repeated measurements were assessed by one-way ANOVA followed by Dunnett's post hoc test. A P-value of less than 0.05 was considered to be statistically significant. 
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